Table 1.
A. Tumor cAMP levels, LA uptake, 13-HODE formation, [3H]thymidine incorporation into DNA and DNA content during the mid-dark phase (2400 hrs) in tissue-isolated MCF-7 (ER+) human breast cancer xenografts in nude female rats (Study I) exposed to either LD 12:12 or dLEN and treated with either vehicle or tamoxifen (80 μd). Values are means + SD (n =3/group).
| Treatmenta | cAMP (nmol/g tissue) | LA uptake (ng/min/g) | 13-HODE (ng/min/g) Arterial Supply | 13-HODE (ng/min/g) Venous Output | 3H-Thymidine Incorporation (dpms/ug DNA) | DNA Content (mg/g) |
|---|---|---|---|---|---|---|
| dLEN Vehicle | 1.55 ± 0.28 | 3.86 ± 0.73 (34.8 ± 1.7%)ψ | 0 | 6.58 ± 0.71 | 66.5 ± 2.6 | 3.15 ± 0.16 |
| dLEN Tamoxifen | 1.38 ± 0.14 | 3.94 ± 0.49 (35.8 ± 2.7%)ψ | 0 | 6.04 ± 0.65 | 67.4 ± 1.9 | 3.20 ± 0.28 |
| LD 12:12 Vehicle | 0.11 ± 0.05* | 0 | 0 | 0 | 5.6 ± 1.0 * | 2.0 ± 0.1* |
| LD 12:12 Tamoxifen | 0.07 ± 0.02** | 0 | 0 | 0 | 6.5 ± 1.0** | 1.9 ± 0.2** |
| B Tumor cAMP levels, LA uptake, 13-HODE formation, [3H]thymidine incorporation into DNA and DNA content during the mid-dark phase (2400 hrs) in tissue-isolated MCF-7 (ER+) human breast cancer xenografts in nude female rats (Study II) exposed to dLEN and treated with either vehicle, tamoxifen (80 μg/kg/d), melatonin (2.5μg/d), or tamoxifen + melatonin. Values are means + SD (n =3/group). | ||||||
|---|---|---|---|---|---|---|
| Treatmenta | cAMP (nmol/g tissue) | LA uptake (ng/min/g) | 13-HODE (ng/min/g) Arterial Supply | 13-HODE (ng/min/g) Venous Output | 3H-Thymidine Incorporation(dpms/μg DNA) | DNA Content (mg/g) |
| dLEN Vehicle | 1.63 ± 0.20 | 2.5 ± 0.7 (35.3 ± 1.5%)ψ | 0 | 6.9 ± 0.7 | 67.4 ± 1.1 | 3.5 ± 0.2 |
| dLEN Tamoxifen | 1.62 ± 0.22 | 2.6 ± 0.5 (34.4 ± 2.8%)ψ | 0 | 6.8 ± 0.5 | 69.2 ± 3.3 | 3.4 ± 0.2 |
| dLEN Melatonin | 0.16 ± 0.06* | 0 | 0 | 0 | 5.8 ± 1.0* | 2.0 ± 0.1* |
| dLEN Tamoxifen + Melatonin | 0.06 ± 0.02*** | 0 | 0 | 0 | 5.8 ± 0.1 ** | 2.0 ± 0.1** |
Three animals (tumors)/group
(+ SD) tumor weights, MCF-7 (ER+) dLEN group, vehicle treatment = 7.26 ± 0.21 g; tamoxifen treatment = 7.08 ± 0.22 g; LD 12:12 group vehicle treatment = 5.53 ± 0.20 g; tamoxifen treatment = 1.95 ± 0.09 g, respectively. All tumors were harvested at 2400 hrs.
Values expressed as % of arterial LA supply.
p < 0.05 vs. dLEN vehicle
p < 0.05 vs dLEN + tamoxifen.
Three animals (tumors)/group
(± SD) tumor weights, in MCF-7(ER+) dLEN groups, vehicle treatment = 7.26 ± 0.21 g; tamoxifen treatment = 7.08 ± 0.22 g; dLEN melatonin treatment = 5.53 ± 0.20 g; dLEN tamoxifen + melatonin treatment = 1.95 ± 0.09 g respectively. All tumors were harvested at 2400 hrs.
Values expressed as % of arterial LA supply.
p< 0.05 vs. vehicle
p < 0.05 vs. tamoxifen
p < 0.05 vs. tamoxifen and melatonin.